北京北辰实业股份(00588.HK)：预计截至2025年12月31日止年度利润将继续亏损。 越秀地产(00123.HK)：2025年度累计合同销售金额约为1062.1亿元，同比下降约7.3%，约占销售目标的 88.1%。其中12月销售金额约89.96亿元，同比下降约33.4%。 交个朋友控股(01450.HK)：2025年第四季度，集团合计完成商品交易总额(GMV)约人民币64.9亿元，同 比增长约4.34%；2025年累计完成GMV约人民币160.2亿元，同比增长约6.23%。 赛晶科技(00580.HK)：预计2025年度收入约人民币22.5亿元，同比增加约40%，主要由于来自柔性输电 业务领域的收入增加，得益于有关工程订单产品陆续交付及收入确认。 1月15日，恒指早盘一度冲高逾两百点后回落，午后持续维持水下震荡态势，尾盘受半导体板块走强刺 激一度接近翻红。恒生科技指数全天表现疲软跑输大市；截止收盘，恒生指数跌0.28%报26923.62点， 恒生科技指数跌1.35%报5828.35点，国企指数跌0.52%报9266.86点，红筹指数涨0.39%报4153.7点。 盘面上，大型科技股普遍下跌，阿里巴巴跌2 ...

1月15日，港股早盘冲高回落维持低位窄幅震荡走势，截止午盘，恒生指数跌0.55%报26850.78点，恒生 科技指数跌1.83%报5799.85点，国企指数跌0.69%报9250.87点，红筹指数涨0.11%报4142.09点。 盘面上，大型科技股多数走低，阿里巴巴跌2.96%，腾讯控股跌1.34%，京东集团跌1.04%，小米集团涨 0.32%，网易跌1.91%，美团跌0.79%，快手跌3.42%，哔哩哔哩跌2.25%；AI应用相关概念股集体下跌， 昨日领涨的AI医疗股跌幅较大，阿里健康跌9%；旅游及观光板块大跌，携程跌超19%；中资券商股普 跌，中泰期货跌超4%。另外，锂电池股涨幅居前，赣锋锂业涨超5%；三桶油拉升，中石化刷阶段新 高。 企业新闻 中信证券(06030.HK)：发布2025年度业绩快报，实现营业收入人民币748.30亿元，同比增长28.75%；净 利润人民币300.51亿元，同比增长38.46%。 中信银行(00998.HK)：公布2025年度业绩快报，营业总收入为2,124.75亿元，同比减少0.55%；净利润 706.18亿元，同比增长2.98%。 越秀地产(00123.HK)：2025 ...

Core Viewpoint - Hutchison China MediTech Limited (00013) has seen its stock price increase by 2.39% to HKD 23.98 following the announcement of positive results from the SACHI III clinical trial published in The Lancet [6]. Group 1: Company Announcement - On January 14, Hutchison China MediTech announced the results of the SACHI III trial, which studies the combination therapy of Savolitinib (沃瑞沙®) and Osimertinib (泰瑞沙®) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR TKI treatment [6]. - The SACHI study focuses on patients with MET amplification and evaluates the efficacy of the combination therapy [6]. Group 2: Drug Information - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [6]. - Osimertinib is an irreversible third-generation EGFR TKI [6]. - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to be approved in China by June 2025 [6].

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently trading at 24.1 HKD, with a transaction volume of 57.28 million HKD, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Company Announcement - On January 14, Hutchison China MediTech announced the results of the SACHI III study, which evaluates the combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have progressed after first-line EGFR TKI treatment [1] - The SACHI study focuses on patients with MET amplification and demonstrates the efficacy of the combination therapy [1] Group 2: Drug Information - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.9% at HKD 24.1, with a trading volume of HKD 57.28 million, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Study Announcement - The SACHI III study results involve a combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, and commercialized by AstraZeneca [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

1月15日，港股集体低开，其中恒生指数跌0.1%，报26972.36点，恒生科技指数跌0.55%，报5875.78 点，国企指数跌0.11%，报9305.13点，红筹指数平收，报413768点。 北京北辰实业股份(00588.HK)：预计截至2025年12月31日止年度利润将继续亏损。 越秀地产(00123.HK)：2025年度累计合同销售金额约为1062.1亿元，同比下降约7.3%，约占销售目标的 88.1%。其中12月销售金额约89.96亿元，同比下降约33.4%。 交个朋友控股(01450.HK)：2025年第四季度，集团合计完成商品交易总额(GMV)约人民币64.9亿元，同 比增长约4.34%；2025年累计完成GMV约人民币160.2亿元，同比增长约6.23%。 赛晶科技(00580.HK)：预计2025年度收入约人民币22.5亿元，同比增加约40%，主要由于来自柔性输电 业务领域的收入增加，得益于有关工程订单产品陆续交付及收入确认。 中广核新能源(01811.HK)：2025年累计完成发电量1.9万吉瓦时，同比减少0.8%。其中，中国风电项目 减少0.4%，中国太阳能项目增加31.3%，中国燃气项 ...

Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]

Company News - CITIC Securities (06030.HK) reported a revenue of RMB 74.83 billion for the fiscal year 2025, representing a year-on-year increase of 28.75%, and a net profit of RMB 30.05 billion, up 38.46% year-on-year [2] - CITIC Bank (00998.HK) announced a total revenue of RMB 212.48 billion for 2025, a slight decrease of 0.55% year-on-year, while net profit increased by 2.98% to RMB 70.62 billion [2] - Beijing North Star Industrial (00588.HK) expects to continue reporting losses for the fiscal year ending December 31, 2025 [3] - Yuexiu Property (00123.HK) reported a cumulative contract sales amount of approximately RMB 106.21 billion for 2025, a decline of about 7.3% year-on-year, achieving 88.1% of its sales target [3] - Jiao Ge Peng You Holdings (01450.HK) achieved a total GMV of approximately RMB 6.49 billion in Q4 2025, a year-on-year increase of about 4.34%, with a cumulative GMV of RMB 16.02 billion for the year, up 6.23% [3] - Sai Jing Technology (00580.HK) anticipates a revenue of approximately RMB 2.25 billion for 2025, reflecting a year-on-year increase of about 40% due to increased revenue from flexible transmission business [3] - China General Nuclear Power New Energy (01811.HK) reported a cumulative power generation of 19,000 GWh for 2025, a decrease of 0.8% year-on-year, with variations in different energy sources [3] - Morning News Technology (02000.HK) reported an unaudited revenue of HKD 397 million for 2025, a decrease of 7.4% year-on-year [3] Financing and Buyback Activities - Chow Tai Fook Enterprises (00659.HK) applied for the registration of debt financing instruments totaling no more than RMB 5 billion [7] - Tencent Holdings (00700.HK) repurchased 1.006 million shares at a cost of approximately HKD 636 million, with repurchase prices ranging from HKD 626 to HKD 638 [7] - Xiaomi Group-W (01810.HK) repurchased 4 million shares for approximately HKD 151 million, with repurchase prices between HKD 37.61 and HKD 42.50 [7] Research and Development - Hutchison China MediTech (00013.HK) announced the publication of SACHI III study results in The Lancet [4] - Laka Pharmaceuticals-B (02105.HK) had its clinical trial application for the new drug LAE118 accepted by the U.S. FDA [5] Other News - Yuanxu Technology (08637.HK) announced a short suspension of trading starting January 14, pending the release of insider information [6] - Haidilao (06862.HK) redeemed USD 600 million of its 2.150% notes due in 2026 [2]

Core Viewpoint - The announcement by Hutchison China MediTech Limited (和黄医药) regarding the publication of the SACHI III study results in The Lancet highlights the efficacy of the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification who have progressed after first-line TKI treatment [1][2]. Group 1: Study Results - The SACHI study demonstrates that the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) significantly improves treatment outcomes for patients with MET amplification [1][2]. - The data from the SACHI study indicates that the combination therapy has been approved in China as of June 2025 [1]. Group 2: Expert Commentary - Professor Lu Shun, a principal investigator of the SACHI study, emphasized that the results provide strong evidence for the effectiveness of the combination therapy in addressing MET amplification, a key resistance mechanism in challenging patient populations [2]. - The study also noted consistent efficacy in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for a broader patient base [2]. - The combination therapy offers a convenient and well-tolerated all-oral treatment option for patients in need of new therapies [2].

Core Viewpoint - The results of the SACHI III study, which evaluates the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification, have been published in The Lancet, indicating significant clinical benefits [1][2]. Group 1: Study Overview - The SACHI study focuses on the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) for patients who have progressed after first-line EGFR TKI treatment [1]. - The combination therapy has been approved in China for use starting June 2025 based on the data from the SACHI study [1]. Group 2: Clinical Implications - The data from the SACHI study provides strong evidence that the combination therapy significantly improves treatment outcomes for patients with MET amplification and EGFR mutations [2]. - The study highlights the ability of the combination therapy to address MET amplification, a key resistance mechanism, offering clinically meaningful improvements for challenging patient populations [2]. - Notably, consistent efficacy was observed in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for broader application [2].